GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biovail Corporation (BVF) [hlAlert]

Rating:
Overweight
BVF
up 1,569.50 %

Biovail Corporation (BVF) rated Overweight by JP Morgan

Posted on: Friday,  Sep 25, 2009  8:25 AM ET by JP Morgan

JP Morgan rated Overweight Valeant Pharmaceuticals International Inc (NYSE: VRX) on 09/25/2009, when the stock price was $14.07.
Since then, Valeant Pharmaceuticals International Inc has gained 1569.51% as of 01/06/2016's recent price of $234.90.
If you would have followed this JP Morgan's recommendation on VRX, you would have gained 1569.5% of your investment in 2294 days.

Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. The Company has various research and development, clinical research, manufacturing and commercial operations located in Barbados, Canada, the United States and Puerto Rico. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. On September 16, 2008, Biovail acquired Prestwick Pharmaceuticals, Inc.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy